69 results on '"Lederer, David J"'
Search Results
2. Blood eosinophils and FeNO are prognostic and predictive biomarkers in childhood asthma
3. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study
4. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE study
5. Subphenotypes of frailty in lung transplant candidates
6. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
7. Development of the Lung Transplant Frailty Scale (LT-FS)
8. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
9. ASSESSMENT OF THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN CHILDREN WITH ASTHMA (LIBERTY ASTHMA EXCURSION STUDY)
10. Effect of positive airway pressure therapy of obstructive sleep apnea on circulating Angiopoietin-2
11. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma
12. Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease
13. Baseline SARS-CoV-2 Viral Load Is Associated with Disease Severity and Clinical Outcomes in Hospitalised Patients with COVID-19: Post-Hoc Analyses of a Phase 2/3 Multicentre Trial
14. Extended post ex-vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a multicentric study
15. Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults
16. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
17. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
18. Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study
19. A nonlinear relationship between visceral adipose tissue and frailty in adult lung transplant candidates
20. Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis
21. Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study
22. Modeling of Fibrotic Lung Disease Using 3D Organoids Derived from Human Pluripotent Stem Cells
23. Surfactant protein A and D polymorphisms and methylprednisolone pharmacogenetics in donor lungs
24. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis
25. Bidirectional transfer of Anelloviridae lineages between graft and host during lung transplantation
26. Pamrevlumab (FG-3019), an Anti-Connective Tissue Growth Factor Therapy for Idiopathic Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Trial
27. Focus on Idiopathic Pulmonary Fibrosis
28. Frailty phenotypes and mortality after lung transplantation: A prospective cohort study
29. Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis
30. Serum 25-Hydroxyvitamin D Concentrations Are Associated with Computed Tomography Markers of Subclinical Interstitial Lung Disease among Community-Dwelling Adults in the Multi-Ethnic Study of Atherosclerosis (MESA)
31. Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease
32. A novel patient-centered “intention-to-treat” metric of U.S. lung transplant center performance
33. A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
34. Frailty and maximal exercise capacity in adult lung transplant candidates
35. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial
36. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
37. Primary graft dysfunction: Long-term physical function outcomes among lung transplant recipients
38. The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia
39. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis
40. A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
41. The feasibility of measuring frailty to predict disability and mortality in older medical intensive care unit survivors
42. Lung Transplantation and Atrial Septostomy in Pulmonary Arterial Hypertension
43. Latent Class Analysis Identifies Distinct Phenotypes of Primary Graft Dysfunction After Lung Transplantation
44. Disparities in lung transplantation
45. A Prognostic Model for 6-Month Mortality in Elderly Survivors of Critical Illness
46. Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation
47. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation
48. A comparison of single breath and re-breathe diffusing capacity in emphysema patients and controls
49. Postoperative Estradiol Levels Associate With Development of Primary Graft Dysfunction in Lung Transplantation Patients
50. Effect of Single vs Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.